In this work, it was found that tumor cell-targeted PDT could simultaneously upregulate DR4 and DR5 in HT29 cells, thus drastically sensitizing HT29 cells to tumor-homing RGR-TRAIL (Figure 4(E–G)), which was consistent with our previous work (She et al., 2021). The gene discussed is TNFSF10; the disease is neoplasm.